Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)

Page 1 of 9

Acorda Therapeutics Inc (NASDAQ:ACOR): Matt Sirovich And Jeremy Mindich’s Scopia Capital filed an amended 13D.

You can check out Scopia Capital’s latest holdings and filings here.

Please follow Scopia Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Scopia Capital or update its stock holdings.

Matt Sirovich And Jeremy Mindich
Matt Sirovich And Jeremy Mindich
Scopia Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Scopia Capital Management 0 8,474,728 0 8,474,728 8,474,728 18.1%
Scopia Management, Inc 0 8,474,728 0 8,474,728 8,474,728 18.1%
Matthew Sirovich 0 8,474,728 0 8,474,728 8,474,728 18.1%
Jeremy Mindich 0 8,474,728 0 8,474,728 8,474,728 18.1%
Matt Sirovich And Jeremy Mindich
Matt Sirovich And Jeremy Mindich
Scopia Capital

Page 1 of 9 – SEC Filing








(Amendment No. 2)*



Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title and Class of Securities)


(CUSIP Number)

Samantha Nasello

Scopia Capital Management LP

152 West 57th St., 33rd Floor

New York, NY 10019


(Name, Address and Telephone Number of Person Authorized to Receive Notices and

February 27, 2018

(Date of Event Which Requires Filing of Statement)



If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule
13d-1(f) or Rule 13d-1(g), check the following box.  ☒

Note. Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes)

Follow Acorda Therapeutics Inc (NASDAQ:ACOR)
Trade (NASDAQ:ACOR) Now!
Page 1 of 9